Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma

doi:10.1007/s00330-018-5912-2

	Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma
	Song, Jiangdian 1,2; Tian, Jie 3; Zhang, Lina 2; Qu, Xiujuan 2; Qian, Wei 4,5; Zheng, Bin 5,6; Zhang, Lina 7; Zhao, Jia 2; Niu, Meng 8; Zhou, Mu 9; Cui, Lei 1; Liu, Yunpeng 2; Zhao, Mingfang 2
发表期刊	EUROPEAN RADIOLOGY
ISSN	0938-7994
	2019-05-01
卷号	29 期号:5 页码:2388-2398
通讯作者	Liu, Yunpeng(ypliu@cmu.edu.cn) ; Zhao, Mingfang(mfzhao@cmu.edu.cn)
摘要	ObjectivesTo establish a pre-therapy prognostic index model (PIM) of the first-line chemotherapy aiming to achieve accurate prediction of time to progression (TTP) and overall survival among the patients diagnosed with locally advanced (stage III) or distant metastasis (stage IV) lung squamous cell carcinoma (LSCC).MethodsNinety-six LSCC patients treated with first-line chemotherapy were retrospectively enrolled to build the model. Fourteen epidermal growth factor receptor (EGFR)-mutant LSCC patients treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy were enrolled for validation dataset. From CT images, 56,000 phenotype features were initially computed. PIM was constructed by integrating a CT phenotype signature selected by the least absolute shrinkage and selection operator and the significant blood-based biomarkers selected by multivariate Cox regression. PIM was then compared with other four prognostic models constructed by the CT phenotype signature, clinical factors, post-therapy tumor response, and Glasgow Prognostic Score.ResultsThe signature includes eight optimal features extracted from co-occurrence, run length, and Gabor features. By using PIM, chemotherapy efficacy of patients categorized in the low-risk, intermediate-risk, and high-risk progression subgroups (median TTP=7.2months, 3.4months, and 1.8months, respectively) was significantly different (p<0.0001, log-rank test). Chemotherapy efficacy of the low-risk progression subgroup was comparable with EGFR-TKI therapy (p=0.835, log-rank test). Prognostic prediction of chemotherapy efficacy by PIM was significantly higher than other models (p<0.05, z test).ConclusionThe study demonstrated that the PIM yielded significantly higher performance to identify individual stage III-IV LSCC patients who can potentially benefit most from first-line chemotherapy, and predict the risk of failure from chemotherapy for individual patients.Key Points center dot TTP and OS of first-line chemotherapy in individual stage III-IV LSCC patients could be predicted by pre-therapy blood-based biomarkers and image-based signatures.center dot Risk status of pre-therapy indicators affected the efficacy of first-line chemotherapy in stage III-IV LSCC patients.center dot Those stage III-IV LSCC patients who were able to achieve similar efficacy to EGFR-TKI therapy through chemotherapy were identified.
关键词	Biomarkers Tumor Carcinoma Squamous cell Prognosis
DOI	10.1007/s00330-018-5912-2
关键词[WOS]	OPEN-LABEL ; HEPATOCELLULAR-CARCINOMA ; IMAGING PHENOTYPES ; CANCER ; PREDICTION ; SURVIVAL ; PHASE-3 ; MULTICENTER ; DOCETAXEL ; RISK
收录类别	SCI
语种	英语
资助项目	National Key R&D Program of China[2016YFC1303800] ; China Postdoctoral Science Foundation[2018 M630310] ; National Key R&D Program of China[2016YFC1303800] ; China Postdoctoral Science Foundation[2018 M630310]
项目资助者	National Key R&D Program of China ; China Postdoctoral Science Foundation
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
WOS类目	Radiology, Nuclear Medicine & Medical Imaging
WOS记录号	WOS:000463157200025
出版者	SPRINGER
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/24917
专题	中国科学院分子影像重点实验室
通讯作者	Liu, Yunpeng; Zhao, Mingfang
作者单位	1.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China 2.China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Liaoning, Peoples R China 3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China 4.Univ Texas El Paso, Coll Engn, El Paso, TX 79968 USA 5.Northeastern Univ, Sino Dutch Biomed Engn Sch, Shenyang, Liaoning, Peoples R China 6.Univ Oklahoma, Med & Biol Informat Engn, Norman, OK 73019 USA 7.China Med Univ, Hosp 1, Dept Radiol, Shenyang, Liaoning, Peoples R China 8.China Med Univ, Hosp 1, Dept Intervent Therapy, Shenyang, Liaoning, Peoples R China 9.Stanford Univ, Dept Radiol, AIMI Ctr, San Francisco, CA USA
推荐引用方式 GB/T 7714	Song, Jiangdian,Tian, Jie,Zhang, Lina,et al. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma[J]. EUROPEAN RADIOLOGY,2019,29(5):2388-2398.
APA	Song, Jiangdian.,Tian, Jie.,Zhang, Lina.,Qu, Xiujuan.,Qian, Wei.,...&Zhao, Mingfang.(2019).Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.EUROPEAN RADIOLOGY,29(5),2388-2398.
MLA	Song, Jiangdian,et al."Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma".EUROPEAN RADIOLOGY 29.5(2019):2388-2398.